Search - tctmd.com

Displaying 1 - 20 of 113

Sort: Relevancy | Date

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

News Conference News AHA 2025

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

Michael O'Riordan

November 11, 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

October 27, 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

News Conference News ESC 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

September 05, 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

News Conference News ESC 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Michael O'Riordan

September 04, 2025

Bioresorbable Scaffold for CLTI Appears to Be an Economical Option: LIFE-BTK

News Conference News CX Symposium 2025

Bioresorbable Scaffold for CLTI Appears to Be an Economical Option: LIFE-BTK

April 24, 2025

It’s Been 1 Year Since Medicare’s NCD for Carotid Stenting: What Now?

News Conference News VIVA 2024

It’s Been 1 Year Since Medicare’s NCD for Carotid Stenting: What Now?

November 14, 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

News Conference News VIVA 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

November 11, 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

News Conference News VIVA 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

November 06, 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

November 05, 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

October 29, 2024

No Go for No-Touch SVG Harvesting in CABG Surgery: SWEDEGRAFT

News Conference News ESC 2024

No Go for No-Touch SVG Harvesting in CABG Surgery: SWEDEGRAFT

Michael O'Riordan

August 31, 2024

POLMIDES: Hybrid Revascularization Bests CABG For 10-Year Survival

News Conference News EuroPCR 2024

POLMIDES: Hybrid Revascularization Bests CABG For 10-Year Survival

Yael L. Maxwell

May 22, 2024

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

News Conference News SCAI 2024

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

May 10, 2024

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

News Conference News ACC 2024

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

April 10, 2024

Oral Device Noninferior to CPAP for Reducing BP in Sleep Apnea: CRESCENT

News Conference News ACC 2024

Oral Device Noninferior to CPAP for Reducing BP in Sleep Apnea: CRESCENT

April 06, 2024

Durable 1-Year Outcomes With Coronary Sinus Shunt for HF: ALT-FLOW EFS

News Conference News THT 2024

Durable 1-Year Outcomes With Coronary Sinus Shunt for HF: ALT-FLOW EFS

Michael O'Riordan

March 06, 2024

Does Thrombolysis Have a Role in a Primary-PCI World? Experts Hash It Out

News Conference News TCT 2023

Does Thrombolysis Have a Role in a Primary-PCI World? Experts Hash It Out

Michael O'Riordan

October 25, 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

October 25, 2023

Comparing DCBs in De Novo CAD: Drugs, Design Matter

News Conference News TCT 2023

Comparing DCBs in De Novo CAD: Drugs, Design Matter

October 25, 2023

Watchman, Amulet LAAO Devices Have Similar Leak Rates at About 1 Year

News Conference News TCT 2023

Watchman, Amulet LAAO Devices Have Similar Leak Rates at About 1 Year

October 25, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.